Spots Global Cancer Trial Database for Liquid Biopsy for Early Non-small Lung Cancer Detection

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Liquid Biopsy for Early Non-small Lung Cancer Detection

Official Title: Liquid Biopsy to Distinguish Malignant From Benign Pulmonary Nodules and to Monitor Response to Therapy

Study ID: NCT05462795

Conditions

Non Small-cell Lung Cancer

Interventions

Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule

Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection

Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer

Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease

Study Description

Brief Summary: This clinical trial will assess the performance of a liquid biopsy assay to identify cancer in indeterminant pulmonary nodules identified by CT screening of high-risk individuals and evaluate the capability of the liquid biopsy assay to monitor response to surgical resection.

Detailed Description: This clinical study examines the feasibility of a liquid biopsy methylation assay to detect non-small lung cancer. First, the investigators will apply their liquid biopsy assay to screen for lung cancer in indeterminate pulmonary nodules suspicious for cancer. Second, the investigators will assess the utility of liquid biopsy to assess tumor dynamics after surgical resection with curative intent. Third, the investigators will assess the presence or absence of this methylation assay in healthy normal persons without a history of lung cancer.